Download Free Orphans And Incentives Book in PDF and EPUB Free Download. You can read online Orphans And Incentives and write the review.

Infectious diseases remain a leading cause of prolonged illness, premature mortality, and soaring health costs. In the United States in 1995, infectious diseases were the third leading cause of death, right behind heart disease and cancer. Mortality is mounting over time, owing to HIV/AIDS, pneumonia, and septicemia, with drug resistance playing an ever-increasing role in each of these disease categories. This book, a report from a Forum on Emerging Infections workshop, focuses on product areas where returns from the market might be perceived as being too small or too complicated by other factors to compete in industrial portfolios with other demands for investment. Vaccines are quintessential examples of such products. The lessons learned fall into four areas, including what makes intersectoral collaboration a reality, the notion of a product life cycle, the implications of divergent sectoral mandates and concepts of risk, and the roles of advocacy and public education. The summary contains an examination of the Children's Vaccine Initiative and other models, an industry perspective on the emerging infections agenda, and legal and regulatory issues.
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Jails, hospitals, and strip joints; the celebrations of straight-A report cards, graduations, and Congressional honors - as the children demonstrate their humor, hope, and resilience in trying to overcome their society's failure.
The HIV/AIDS epidemic in Africa has defined the childhoods of an entire generation. Over the past twenty years, international NGOs and charities have devoted immense attention to the millions of African children orphaned by the disease. But in Crying for Our Elders, anthropologist Kristen E. Cheney argues that these humanitarian groups have misread the ‘orphan crisis’. She explains how the global humanitarian focus on orphanhood often elides the social and political circumstances that actually present the greatest adversity to vulnerable children—in effect deepening the crisis and thereby affecting children’s lives as irrevocably as HIV/AIDS itself. Through ethnographic fieldwork and collaborative research with children in Uganda, Cheney traces how the “best interest” principle that governs children’s’ rights can stigmatize orphans and leave children in the post-antiretroviral era even more vulnerable to exploitation. She details the dramatic effects this has on traditional family support and child protection and stresses child empowerment over pity. Crying for Our Elders advances current discussions on humanitarianism, children’s studies, orphanhood, and kinship. By exploring the unique experience of AIDS orphanhood through the eyes of children, caregivers, and policymakers, Cheney shows that despite the extreme challenges of growing up in the era of HIV/AIDS, the post-ARV generation still holds out hope for the future.
Undertaken at orphanages in Russia, this study tests the role of early social and emotion experience in the development of children. Children were exposed to either multiple caregivers who performed routine duties in a perfunctory manner with minimal interaction or fewer caregivers who were trained to engage in warm, responsive, and developmentally appropriate interactions during routine care. Engaged and responsive caregivers were associated with substantial improvements in child development and these findings provide a rationale for making similar improvements in other institutions, programs, and organizations.
Grabbed up by the United States government and thrown into training camps, orphans around the country have been raised to become America's next generation of super-spies. Now, as adults, they live among us, ready for "the family" to call them back into action. Collects the complete four-issue limited series
Why the global health project to avert emerging microbes continually fails In 1989, a group of U.S. government scientists met to discuss some surprising findings: new diseases were appearing around the world, and viruses that they thought long vanquished were resurfacing. Their appearance heralded a future perpetually threatened by unforeseeable biological risks, sparking a new concept of disease: the “emerging microbe.” With the Cold War nearing its end, American scientists and security experts turned to confront this new “enemy,” redirecting national security against its risky horizons. In order to be fought, emerging microbes first needed to be made perceptible; but how could something immaterial, unknowable, and ever mutating be coaxed into visibility, knowability, and operability? Microbial Resolution charts the U.S.-led war on the emerging microbe to show how their uncertain futures were transformed into objects of global science and security. Moving beyond familiar accounts that link scientific knowledge production to optical practices of visualizing the invisible, Gloria Chan-Sook Kim develops a theory of “microbial resolution” to analyze the complex problematic that arises when dealing with these entities: what can be seen when there is nothing to see? Through a syncretic analysis of data mining, animal-tracking technologies, media networks, computer-modeled futures, and global ecologies and infrastructures, she shows how a visual impasse—the impossibility of seeing microbial futures—forms the basis for new modes of perceiving, knowing, and governing in the present. Timely and thought provoking, Microbial Resolution opens up the rich paradoxes, irreconcilabilities, and failures inherent in this project and demonstrates how these tensions profoundly animate twenty-first-century epistemologies, aesthetics, affects, and ecologies.
Adoption has long been enmeshed in the politics of abortion. But as award-winning journalist Joyce makes clear, adoption has lately become entangled in the conservative Christian agenda.
Orphan drugs are designated drug substances that are intended to treat rare or ‘orphan’ diseases. More than 7000 rare diseases are known that collectively affect some 6-7% of the developed world’s population; however, individually, any single, rare disease may only affect a handful of people making them commercially unattractive for the biopharmaceutical industry to target. Ground breaking legislation, starting with the Orphan Drug Act that was passed in the US in 1983 to provide financial incentives for companies to develop orphan drugs, has sparked ever increasing interest from biopharmaceutical companies to tackle rare diseases. These developments have made rare diseases, and the orphan drugs that treat them, sufficiently attractive to pharmaceutical development and many pharmaceutical companies now have research units dedicated to this area of research. It is therefore timely to review the area of orphan drugs and some of the basic science, drug discovery and regulatory factors that underpin this important, and growing, area of biomedical research. Written by a combination of academic and industry experts working in the field, this text brings together expert authors in the regulatory, drug development, genetics, biochemistry, patient advocacy group, medicinal chemistry and commercial domains to create a unique and timely reference for all biomedical researchers interested in finding out more about orphan drugs and the rare diseases they treat. Providing an up-to-date monograph, this book covers the basic science, drug discovery and regulatory elements behind orphan drugs and will appeal to medicinal and pharmaceutical chemists, biochemists and anyone working within the fields of rare disease research and drug development or pharmaceuticals in industry or academia.
Infectious diseases remain a leading cause of prolonged illness, premature mortality, and soaring health costs. In the United States in 1995, infectious diseases were the third leading cause of death, right behind heart disease and cancer. Mortality is mounting over time, owing to HIV/AIDS, pneumonia, and septicemia, with drug resistance playing an ever-increasing role in each of these disease categories. This book, a report from a Forum on Emerging Infections workshop, focuses on product areas where returns from the market might be perceived as being too small or too complicated by other factors to compete in industrial portfolios with other demands for investment. Vaccines are quintessential examples of such products. The lessons learned fall into four areas, including what makes intersectoral collaboration a reality, the notion of a product life cycle, the implications of divergent sectoral mandates and concepts of risk, and the roles of advocacy and public education. The summary contains an examination of the Children's Vaccine Initiative and other models, an industry perspective on the emerging infections agenda, and legal and regulatory issues.